NEW YORK (GenomeWeb News) – BioTime subsidiary OncoCyte today announced that it will collaborate with the Wistar Institute on the development of a gene expression-based lung cancer test.

Under the agreement, OncoCyte scientists will use the firm's cancer diagnostic test, PanC-Dx, to analyze levels of tumor-associated proteins in blood samples from patients in an ongoing study conducted by Wistar. Scheduled to wrap up in mid-2104, two thirds of the planned total of 600 samples have already been collected in the study.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: factors affecting the success of whole-genome sequencing for routine clinical diagnosis, and more.

A large meta-analysis from an international team reports that nature and nurture have about an equal overall influence on human traits.

The Lasker Foundation's Claire Pomeroy laments the state of NIH funding at Forbes.

Social media is changing how scientists discuss research, as tweets from University of Chicago's Yoav Gilad about a Mouse ENCODE paper have shown, Nature reports.